Aleniglipron Hepatic Impairment Study
A Phase 1, Single-Dose, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Aleniglipron Pharmacokinetics
The purpose of this study is to evaluate the PK of aleniglipron in participants with Hepatic Impairment to establish scientifically guided dosing recommendations in these special patient populations.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Medical Director
- Phone Number: 650-457-1959
- Email: GSBRClinicalTrials@Structuretx.com
Study Locations
-
-
Florida
-
Orlando, Florida, United States, 32809
- Recruiting
- Research Site
-
Contact:
- Medical Director
- Phone Number: 650-457-1959
- Email: GSBRClinicalTrials@Structuretx.com
-
-
Texas
-
San Antonio, Texas, United States, 78215
- Recruiting
- Research Site
-
Contact:
- Medical Director
- Phone Number: 650-457-1959
- Email: GSBRClinicalTrials@Structuretx.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Is an adult, male or female, ≥ 18 to 85 years of age (inclusive), at screening.
- Female and male participants must follow protocol-specified contraception guidance as described in Section 5.4.2.1 and Section 5.4.2.2.
- Is a continuous non-smoker or smoker (≤ 10 cigarettes per day or equivalent) for at least 3 months prior to dosing. Participants must agree to maintain the same smoking status (i.e., smoker or non-smoker) from screening and until after the last PK sample collection.
- BMI ≥ 17.0 and ≤ 40.0 kg/m2 and weight of at least 40.0 kg at screening.
- Understands the study procedures in the ICF and be willing and able to comply with the protocol and communicate effectively with study personnel.
Exclusion Criteria:
- Is mentally or legally incapacitated or has significant emotional problems at the time of screening or expected during the conduct of the study.
- History or presence of alcohol or drug abuse (including participants with symptoms of cannabis disorder) within the past 6 months prior to the dosing.
- History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds.
- Female participant with a positive serum pregnancy test at screening or at check-in or who is lactating or breastfeeding.
- Has positive drug results at screening or at check-in, unless the positive drug screen is due to prescription drug use that is approved by the PI or designee. Participants with a positive result for cannabinoids may be enrolled at the discretion of the PI or designee and the Sponsor.
- Has taken medications intended to promote weight loss within 3 months or 5 half-lives, whichever is longer, prior to screening, including, but not limited to GLP-1 RAs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Participants will receive aleniglipron administered orally Part 1
Aleniglipron administered orally. |
administered orally |
|
Experimental: Participants will receive aleniglipron administered orally Part 2
Aleniglipron administered orally. |
administered orally |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
PK parameters including but not limited to AUC0-t
Time Frame: Baseline to Day 5 (Part 1)
|
Baseline to Day 5 (Part 1)
|
|
PK parameters including but not limited to AUC0-inf
Time Frame: Baseline to Day 5 (Part 1)
|
Baseline to Day 5 (Part 1)
|
|
PK parameters including but not limited to Cmax
Time Frame: Baseline to Day 5 (Part 1)
|
Baseline to Day 5 (Part 1)
|
|
PK parameters including but not limited to AUC0-t
Time Frame: Baseline to Day 5 (Part 2)
|
Baseline to Day 5 (Part 2)
|
|
PK parameters including but not limited to AUC0-inf
Time Frame: Baseline to Day 5 (Part 2)
|
Baseline to Day 5 (Part 2)
|
|
PK parameters including but not limited to Cmax
Time Frame: Baseline to Day 5 (Part 2)
|
Baseline to Day 5 (Part 2)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- GSBR-1290-20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.